Seeking Alpha

Genzyme (GENZ +2.1%) is unexpectedly softening in its resistance to Sanofi-Aventis' (SNY +0.5%)...

Genzyme (GENZ +2.1%) is unexpectedly softening in its resistance to Sanofi-Aventis' (SNY +0.5%) courtship, apparently after being rebuffed in reaching out to other possible buyers including Pfizer (PFE), Johnson & Johnson (JNJ) and Merck (MRK). Currently under discussion: a CVR that would give Genzyme upside if leukemia drug Campath proves effective against MS.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs